Montreal, Canada

Sanijia Xu

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Revagenix, Inc.. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sanijia Xu. Retrieved from https://idiyas.com/inventor/sanijia-xu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Journey of Sanijia Xu

Introduction

Sanijia Xu is an accomplished inventor based in Montreal, Canada, known for his contributions to the field of medicinal chemistry. His work focuses on the development of novel methods for synthesizing antibacterial compounds, demonstrating his commitment to advancing healthcare solutions.

Latest Patents

Sanijia Xu holds a patent for the "Modular synthesis of aminoglycosides." This patent pertains to innovative methods for preparing antibacterial aminoglycoside compounds, highlighting his expertise in creating effective pharmaceutical solutions that address bacterial infections.

Career Highlights

Currently, Sanijia Xu is employed at Revagenix, Inc., where he continues to explore cutting-edge research in the pharmaceutical industry. His dedication to innovative approaches in drug development sets him apart as a notable figure in his field.

Collaborations

Throughout his career, Sanijia has collaborated with talented professionals, including Andrew Calabrese and Timothy Robert Kane. These collaborations have fostered a dynamic environment for creativity and innovation, allowing for the exchange of ideas and expertise.

Conclusion

Sanijia Xu's innovative spirit and dedication to advancements in medicine make him a prominent inventor in the field. With his contributions, he continues to pave the way for new treatments and solutions that have the potential to improve patient outcomes and enhance public health.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…